You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFenoprofen
Accession NumberDB00573  (APRD00970)
TypeSmall Molecule
GroupsApproved
DescriptionAn anti-inflammatory analgesic and antipyretic highly bound to plasma proteins. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding. [PubChem]
Structure
Thumb
Synonyms
(+-)-2-(3-Phenoxyphenyl)propionic acid
(+/-)-fenoprofen
(+/-)-m-phenoxyhydratropic acid
2-(3-phenoxyphenyl)propionic acid
2-(m-phenoxyphenyl)propionic acid
3-phenoxyhydratropic acid
alpha-(m-Phenoxyphenyl)propionic acid
alpha-Methyl-3-phenoxybenzeneacetic acid
DL-2-(3-phenoxyphenyl)propionic acid
Fenoprofen
Fénoprofène
Fenoprofeno
Fenoprofenum
External Identifiers
  • 69323
  • Lilly 53858
  • LILLY-53858
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fenoprofencapsule400 mg/1oralbryant ranch prepack2014-07-14Not applicableUs
Fenoprofencapsule400 mg/1oralPreferred Pharmaceuticals, Inc.2014-08-20Not applicableUs
Fenoprofencapsule400 mg/1oralKLE 2, Inc.2014-07-142015-12-29Us
Fenoprofencapsule400 mg/1oralMedsource Pharmaceuticals2014-07-14Not applicableUs
Fenoprofen Calciumcapsule400 mg/1oralXspire Pharma Llc2015-08-05Not applicableUs
Nalfoncapsule400 mg/1oralXspire Pharma2012-08-27Not applicableUs
Nalfoncapsule200 mg/1oralXspire Pharma2012-08-27Not applicableUs
Nalfon Cap 300mgcapsule300 mgoralEli Lilly Canada Inc1975-12-312002-07-26Canada
Nalfon Tab 600mgtablet600 mgoralEli Lilly Canada Inc1975-12-312002-07-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fenoprofen Calciumtablet, film coated600 mg/1oralMylan Pharmaceuticals Inc.2012-11-14Not applicableUs
Fenoprofen Calciumtablet, film coated600 mg/1oralPd Rx Pharmaceuticals, Inc.2009-11-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FeilinHengshan Pharmaceutical
FenopronTypharm
FepronSheng Chung Tang
KimpronDaewoong
NalgésicSciencex
NonsicHasan
NoprofenPanion & BF
TrandorBiolab
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fenoprofen calcium
53746-45-5
Thumb
  • InChI Key: LZPBLUATTGKZBH-UHFFFAOYSA-L
  • Monoisotopic Mass: 558.1566588
  • Average Mass: 558.64
DBSALT001038
Fenoprofen sodium
34691-31-1
Thumb
  • InChI Key: WVKIYGXHDKTNFO-UHFFFAOYSA-M
  • Monoisotopic Mass: 264.07623856
  • Average Mass: 264.256
DBSALT001848
Categories
UNIIRA33EAC7KY
CAS number29679-58-1
WeightAverage: 242.2699
Monoisotopic: 242.094294314
Chemical FormulaC15H14O3
InChI KeyInChIKey=RDJGLLICXDHJDY-UHFFFAOYSA-N
InChI
InChI=1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)
IUPAC Name
2-(3-phenoxyphenyl)propanoic acid
SMILES
CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylethers
Direct ParentDiphenylethers
Alternative Parents
Substituents
  • Diphenylether
  • 2-phenylpropanoic-acid
  • Diaryl ether
  • Phenylacetate
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Also for the relief of mild to moderate pain.
PharmacodynamicsFenoprofen is a propionic acid derivative with analgesic, antiinflammatory and antipyretic properties. Fenoprofen inhibits prostaglandin synthesis by decreasing the enzyme needed for biosynthesis. In patients with rheumatoid arthritis, the anti-inflammatory action of fenoprofen has been evidenced by relief of pain, increase in grip strength, and reductions in joint swelling, duration of morning stiffness, and disease activity (as assessed by both the investigator and the patient). In patients with osteoarthritis, the anti-inflammatory and analgesic effects of fenoprofen have been demonstrated by reduction in tenderness as a response to pressure and reductions in night pain, stiffness, swelling, and overall disease activity (as assessed by both the patient and the investigator). These effects have also been demonstrated by relief of pain with motion and at rest and increased range of motion in involved joints. In patients with rheumatoid arthritis and osteoarthritis, clinical studies have shown fenoprofen to be comparable to aspirin in controlling the aforementioned measures of disease activity, but mild gastrointestinal reactions (nausea, dyspepsia) and tinnitus occurred less frequently in patients treated with fenoprofen than in aspirin-treated patients. It is not known whether fenoprofen causes less peptic ulceration than does aspirin. In patients with pain, the analgesic action of fenoprofen has produced a reduction in pain intensity, an increase in pain relief, improvement in total analgesia scores, and a sustained analgesic effect.
Mechanism of actionFenoprofen's exact mode of action is unknown, but it is thought that prostaglandin synthetase inhibition is involved. Fenoprofen has been shown to inhibit prostaglandin synthetase isolated from bovine seminal vesicles.
Related Articles
AbsorptionRapidly absorbed under fasting conditions, and peak plasma levels of 50 µg/mL are achieved within 2 hours after oral administration of 600 mg doses.
Volume of distributionNot Available
Protein binding99% to albumin.
Metabolism

About 90% of a single oral dose is eliminated within 24 hours as fenoprofen glucuronide and 4'-hydroxyfenoprofen glucuronide, the major urinary metabolites of fenoprofen.

SubstrateEnzymesProduct
Fenoprofen
Not Available
4'-hydroxyfenoprofen glucuronideDetails
Fenoprofen
Not Available
Fenoprofen glucuronideDetails
Route of eliminationNot Available
Half lifePlasma half-life is approximately 3 hours.
ClearanceNot Available
ToxicitySymptoms of overdose appear within several hours and generally involve the gastrointestinal and central nervous systems. They include dyspepsia, nausea, vomiting, abdominal pain, dizziness, headache, ataxia, tinnitus, tremor, drowsiness, and confusion. Hyperpyrexia, tachycardia, hypotension, and acute renal failure may occur rarely following overdose. Respiratory depression and metabolic acidosis have also been reported following overdose with certain NSAIDs.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Fenoprofen Action PathwayDrug actionSMP00696
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9948
Blood Brain Barrier+0.8373
Caco-2 permeable+0.8876
P-glycoprotein substrateNon-substrate0.6587
P-glycoprotein inhibitor INon-inhibitor0.8897
P-glycoprotein inhibitor IINon-inhibitor0.9357
Renal organic cation transporterNon-inhibitor0.8521
CYP450 2C9 substrateNon-substrate0.6883
CYP450 2D6 substrateNon-substrate0.9354
CYP450 3A4 substrateNon-substrate0.6779
CYP450 1A2 substrateInhibitor0.5871
CYP450 2C9 inhibitorNon-inhibitor0.8382
CYP450 2D6 inhibitorNon-inhibitor0.9769
CYP450 2C19 inhibitorNon-inhibitor0.7675
CYP450 3A4 inhibitorNon-inhibitor0.938
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8169
Ames testNon AMES toxic0.9558
CarcinogenicityNon-carcinogens0.7885
BiodegradationReady biodegradable0.5267
Rat acute toxicity1.9985 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9517
hERG inhibition (predictor II)Non-inhibitor0.9414
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • American therapeutics inc
  • Halsey drug co inc
  • Par pharmaceutical inc
  • Quantum pharmics ltd
  • Sandoz inc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Pedinol pharmacal inc
  • Actavis elizabeth llc
  • Clonmel healthcare ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Usl pharma inc
  • Dista products co div eli lilly and co
Packagers
Dosage forms
FormRouteStrength
Capsuleoral400 mg/1
Tablet, film coatedoral600 mg/1
Capsuleoral200 mg/1
Capsuleoral300 mg
Tabletoral600 mg
Prices
Unit descriptionCostUnit
Fenoprofen calcium powder1.59USD g
Fenoprofen Calcium 600 mg tablet1.01USD tablet
Nalfon 200 mg capsule0.91USD capsule
Fenoprofen 600 mg tablet0.88USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point168-171Marshall, W.S.; U.S. Patent 3,600,437; August 17, 1971; assigned to Eli Lilly and Company.
water solubilitySlight (calcium salt)Not Available
logP3.1Not Available
pKa4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0811 mg/mLALOGPS
logP3.87ALOGPS
logP3.65ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)3.96ChemAxon
pKa (Strongest Basic)-8.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity68.18 m3·mol-1ChemAxon
Polarizability25.3 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Marshall, W.S.; U.S. Patent 3,600,437; August 17, 1971; assigned to Eli Lilly and Company.

General ReferencesNot Available
External Links
ATC CodesM01AE04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (141 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabFenoprofen may increase the anticoagulant activities of Abciximab.
AcebutololFenoprofen may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Aceclofenac.
AcenocoumarolFenoprofen may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fenoprofen.
Alendronic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Alendronic acid.
AliskirenFenoprofen may decrease the antihypertensive activities of Aliskiren.
AlprenololFenoprofen may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Fenoprofen.
AmikacinFenoprofen may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideFenoprofen may decrease the antihypertensive activities of Amiloride.
AncrodFenoprofen may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Antipyrine.
Antithrombin III humanFenoprofen may increase the anticoagulant activities of Antithrombin III human.
ApixabanFenoprofen may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Apremilast.
ArdeparinFenoprofen may increase the anticoagulant activities of Ardeparin.
ArgatrobanFenoprofen may increase the anticoagulant activities of Argatroban.
ArotinololFenoprofen may decrease the antihypertensive activities of Arotinolol.
AtenololFenoprofen may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fenoprofen.
BalsalazideFenoprofen may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fenoprofen.
BecaplerminFenoprofen may increase the anticoagulant activities of Becaplermin.
BefunololFenoprofen may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Fenoprofen.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Fenoprofen.
BenoxaprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Benoxaprofen.
BetaxololFenoprofen may decrease the antihypertensive activities of Betaxolol.
BevantololFenoprofen may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Fenoprofen.
BisoprololFenoprofen may decrease the antihypertensive activities of Bisoprolol.
BivalirudinFenoprofen may increase the anticoagulant activities of Bivalirudin.
BopindololFenoprofen may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Bromfenac.
BufuralolFenoprofen may decrease the antihypertensive activities of Bufuralol.
BumetanideFenoprofen may decrease the diuretic activities of Bumetanide.
BupranololFenoprofen may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Fenoprofen.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Fenoprofen.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Fenoprofen.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Fenoprofen.
CarprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Carprofen.
CarteololFenoprofen may decrease the antihypertensive activities of Carteolol.
CarvedilolFenoprofen may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fenoprofen.
CeliprololFenoprofen may decrease the antihypertensive activities of Celiprolol.
CertoparinFenoprofen may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Chloroquine.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fenoprofen.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Fenoprofen.
CholestyramineCholestyramine can cause a decrease in the absorption of Fenoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Fenoprofen.
Citric AcidFenoprofen may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Fenoprofen.
ColesevelamColesevelam can cause a decrease in the absorption of Fenoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Fenoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineFenoprofen may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with D-Limonene.
Dabigatran etexilateFenoprofen may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinFenoprofen may increase the anticoagulant activities of Dalteparin.
DanaparoidFenoprofen may increase the anticoagulant activities of Danaparoid.
DaunorubicinFenoprofen may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Deferasirox.
DesirudinFenoprofen may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Fenoprofen.
DextranFenoprofen may increase the anticoagulant activities of Dextran.
Dextran 40Fenoprofen may increase the anticoagulant activities of Dextran 40.
Dextran 70Fenoprofen may increase the anticoagulant activities of Dextran 70.
Dextran 75Fenoprofen may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Diclofenac.
DicoumarolFenoprofen may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Diflunisal.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Fenoprofen.
DihydrostreptomycinFenoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Fenoprofen.
DoxorubicinFenoprofen may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneFenoprofen may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Droxicam.
Edetic AcidFenoprofen may increase the anticoagulant activities of Edetic Acid.
EdoxabanFenoprofen may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Fenoprofen.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Fenoprofen.
EnoxaparinFenoprofen may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Epirizole.
EpirubicinFenoprofen may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneFenoprofen may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Fenoprofen.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fenoprofen.
EsmololFenoprofen may decrease the antihypertensive activities of Esmolol.
Etacrynic acidFenoprofen may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Fenoprofen.
Ethyl biscoumacetateFenoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Fenoprofen is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fenbufen.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Fenoprofen.
FlunixinThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Flurbiprofen.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Fenoprofen.
Fondaparinux sodiumFenoprofen may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Fenoprofen.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Fenoprofen.
FramycetinFenoprofen may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideFenoprofen may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Fenoprofen.
GentamicinFenoprofen may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Haloperidol.
HeparinFenoprofen may increase the anticoagulant activities of Heparin.
HirulogFenoprofen may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Fenoprofen is combined with HMPL-004.
HydralazineFenoprofen may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Fenoprofen.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Fenoprofen.
Hygromycin BFenoprofen may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Icatibant.
IdarubicinFenoprofen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Fenoprofen.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Fenoprofen.
IndenololFenoprofen may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fenoprofen.
IndoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fenoprofen.
IsoxicamThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Isoxicam.
KanamycinFenoprofen may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fenoprofen.
LabetalolFenoprofen may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Leflunomide.
LepirudinFenoprofen may increase the anticoagulant activities of Lepirudin.
LevobunololFenoprofen may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Fenoprofen.
LithiumThe serum concentration of Lithium can be increased when it is combined with Fenoprofen.
LornoxicamThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Fenoprofen.
LoxoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Fenoprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fenoprofen.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Meloxicam.
MesalazineFenoprofen may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fenoprofen.
MetamizoleThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Fenoprofen.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenoprofen.
MetipranololFenoprofen may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Fenoprofen.
MetoprololFenoprofen may decrease the antihypertensive activities of Metoprolol.
MetrizamideFenoprofen may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Fenoprofen.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Fenoprofen.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Fenoprofen.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fenoprofen.
NadololFenoprofen may decrease the antihypertensive activities of Nadolol.
NadroparinFenoprofen may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Fenoprofen is combined with NCX 4016.
NeomycinFenoprofen may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Nepafenac.
NetilmicinFenoprofen may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Fenoprofen.
OlopatadineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Olopatadine.
OlsalazineFenoprofen may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fenoprofen.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Fenoprofen.
OrgoteinThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Orgotein.
OtamixabanFenoprofen may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Oxaprozin.
OxprenololFenoprofen may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Parecoxib.
ParomomycinFenoprofen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololFenoprofen may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateFenoprofen may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Fenoprofen.
PhenindioneFenoprofen may increase the anticoagulant activities of Phenindione.
PhenprocoumonFenoprofen may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Phenylbutazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fenoprofen.
PindololFenoprofen may decrease the antihypertensive activities of Pindolol.
PiretanideFenoprofen may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fenoprofen.
PlicamycinFenoprofen may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Fenoprofen.
PractololFenoprofen may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Fenoprofen.
ProbenecidThe serum concentration of Fenoprofen can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Propacetamol.
PropranololFenoprofen may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Fenoprofen.
Protein CFenoprofen may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeFenoprofen may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Fenoprofen is combined with PTC299.
PuromycinFenoprofen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Fenoprofen.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Fenoprofen.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Fenoprofen.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Fenoprofen.
ResveratrolThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Resveratrol.
ReviparinFenoprofen may increase the anticoagulant activities of Reviparin.
RibostamycinFenoprofen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Risedronate.
RivaroxabanFenoprofen may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Fenoprofen.
SalicylamideThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fenoprofen.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Fenoprofen.
SeratrodastThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Seratrodast.
SotalolFenoprofen may decrease the antihypertensive activities of Sotalol.
SpectinomycinFenoprofen may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Fenoprofen.
SpironolactoneFenoprofen may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Fenoprofen is combined with SRT501.
StreptomycinFenoprofen may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinFenoprofen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineFenoprofen may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fenoprofen.
SulindacThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Sulindac.
SulodexideFenoprofen may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Suprofen.
TacrolimusFenoprofen may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Fenoprofen.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Fenoprofen.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fenoprofen.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Fenoprofen.
TenofovirThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fenoprofen.
TepoxalinThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tiaprofenic acid.
TiludronateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tiludronate.
TimololFenoprofen may decrease the antihypertensive activities of Timolol.
TobramycinFenoprofen may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fenoprofen.
TorasemideFenoprofen may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Fenoprofen.
TranilastThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Fenoprofen.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Fenoprofen.
TriamtereneFenoprofen may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Fenoprofen.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Valdecoxib.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Fenoprofen.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Fenoprofen.
WarfarinFenoprofen may increase the anticoagulant activities of Warfarin.
XimelagatranFenoprofen may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Zileuton.
Zoledronic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Zomepirac.
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Poggi JC, Barissa GR, Donadi EA, Foss MC, Cunha FQ, Lanchote VL, dos Reis ML: Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus. J Clin Pharmacol. 2006 Nov;46(11):1328-36. [PubMed:17050798 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Poggi JC, Barissa GR, Donadi EA, Foss MC, Cunha FQ, Lanchote VL, dos Reis ML: Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus. J Clin Pharmacol. 2006 Nov;46(11):1328-36. [PubMed:17050798 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23